Market Analysis - Euro Infectious Diseases 2020
Infections and Infectious diseases can be transmitted from animals to people or from one person to another. They can be mild and self-resolve or develop into serious illnesses if left untreated lead to serious illness, long-term consequences or death.
Two contrasting trends are apparent in the infectious disease market. On one hand, the market has witnessed unprecedented growth in the antiviral and vaccine areas since 2010. In particular, the antiviral market has doubled in size—from $20 billion in 2010 to $42 billion in 2017—driven by therapeutic paradigm shifts, especially in the hepatitis C market. On the other hand, there has been a continued decline in the market for systemic antibacterial therapies, with annual revenues dropping from $15 billion in 2010 to $8 billion in 2017, owing to generic competition and limited pipeline innovation. This trend has ultimately contributed to fuelling the political momentum and debate on antimicrobial resistance and raising the awareness on the need to incentivize innovation in antibiotic drug discovery and development.
With a compounded annual growth rate (CAGR) of 3% from 2017– 2022, the infectious disease market is forecast to expand, but more slowly than the overall prescription drug market, for which a CAGR of 6% is expected in the same period. The HIV integrase inhibitor-based class—the leading growth driver—is expected to generate $7.2 billion in additional sales in 2022 compared with 2017, fuelled by Gilead’s (Biktarvy and Genvoya) and GlaxoSmithKline’s (Triumeq) combination therapies. The polyvalent immunoglobulin segment (Shire’s Gammagard and CSL’s Privigen) and pneumococcal vaccines (Pfizer’s Prevnar 13 and Merck & Co.’s Pneumovax) are expected to be the second and third largest therapeutic areas, with 2022 sales of $9.5 billion and $8 billion, respectively.
The global infectious diseases therapeutics market size was valued at USD 46.88 billion in 2016 and is projected to grow at a CAGR of 6.6% during the forecast period. Rising prevalence and increasing expenditure of infectious ailments to boost the penetration rate of treatments of the diseases, rising initiatives for creating awareness about treatments & diagnosis of these conditions, and increasing clinical trial studies for development of new drugs are to be the factors responsible for growth of this market.
The global IVD infectious diseases market size was valued at USD 18.8 billion in 2018. It is likely to exhibit a CAGR of 6.7% from 2018 to 2026. Increasing external funding for research and development (R&D) activities and proactive government initiatives are among the primary growth stimulants for the market.
Based on the types of diseases, the market is segmented into HIV, malaria, hepatitis, influenza, Human Papillomavirus (HPV), and tuberculosis. In 2017, the Ebola segment held the largest share i.e., 49.8% of the market.
US is estimated to grow the rate of 3.37% between 2014- 2019. As per the records, 25% of deaths are mainly due to the infectious diseases. Current market trend shows that North America has the global market for infectious diseases therapeutics due to increasing incidence of infectious diseases due to rise in aging population. Followed by North America highest global market is expected in Asia then followed by the Europe in the global infectious diseases therapeutics market. The main reasons behind the highest market of infectious diseases in the above countries are mainly due to large number of patients and due to increase in government funding.
Infectious Diseases Diagnostics Market:
Infectious disease molecular diagnostics tests include hospitals, blood banks, and reference laboratories. North America has the highest global market for molecular diagnostics followed by Europe due to the market availability of the tests and high occurrence rate of various infectious diseases such as HPV, hepatitis and bacterial infections. Countries like Asia Pacific, Latin America and Middle East are expected to be the potential markets in the coming years.
A closer look at the early and late-stage pipeline broadly confirms the key commercial trends in the market. Figure 3 clearly shows how vaccines and antivirals take the lion’s share of all the development activities: 71% of all the phase 1 and 2 compounds and 60% of all phase 3 assets in pipeline are in one of those two classes. Emerging BioSolutions’ NuThrax (anthrax vaccine) tops the list of the best-selling research and development (R&D) products in 2022, with a sell-side consensus forecast of $870 million according to Evaluate. However, pockets of R&D activities are emerging in the broad systemic antibacterial area and, on a smaller scale, for antimalarial therapies (Box 1).
Fig. 3 | Infectious diseases pipeline. a, Top ten therapy areas in the early-stage (phase 1–2) pipeline (841 candidates). b, Top ten therapy areas in the late-stage (phase 3) pipeline (206 candidates). The pipeline includes potential new molecular entities, new derivatives and potential candidates for new drug applications. Generics, biosimilars or over-the-counter products have not been accounted for. ImG, immunoglobulin G; Proto. Vx, protozoal vaccines; TB, tuberculosis.
Importance & Scope:
Infectious diseases are the second leading cause of world death rate, according to current estimates of the World Health Organization (WHO), the leading killers of children under five years of age. In spite of tremendous progress in Different Countries during the 20th century in reducing infectious disease deaths. When estimated, such deaths rank third behind cardiovascular disease and cancer in this country. With more than 1 billion people had crossed international borders in 2013. This market is expected to increase at a compound annual growth rate (CAGR) of 8.8% to reach $138 billion in 2014. The largest market share taken by antibiotic treatments for bacterial and fungal diseases at 53% of the total infectious disease treatment market. In 2015, 6.5 million individuals were infected with Human Immunodeficiency Virus (HIV) and 28% of the HIV infected people are using antiretroviral therapy. Moreover, increasing availability of targeted drugs is expected to pose significant threat to the market during the forecast period. Global infectious disease therapeutics market size valued at $ 46.88 billion in 2016 and is projected to grow at a CAGR of 6.6% during the forecast period. The Infectious disease diagnostic (IDD) market is estimated to grow at a CAGR of 7.9% to reach $18,156.2 million by 2019.
We live with a crowded and interconnected planet, with a projected global human population of at least 9 billion by 2050. The urbanization of the human population is at the risk of transmission of many infectious agents. Currently, >80% of humans live in developing countries, rising prevalence of infectious ailments, increasing expenditure to boost the penetration rate of treatments of these diseases, rising initiatives and creating awareness about treatments & diagnosis of these conditions, and increasing clinical trial studies for development of new drugs are likely to be the factors responsible for growth of this market. However, lack of awareness and treatments for these disorders and low adoption of treatments are factors to restraint the growth in the coming years.
- Directors, Board Members, Presidents, Vice Presidents, Deans and Head of the Departments
- Infectious Diseases Researchers, Scientists, Faculties, Students
- Infectious Diseases Associations and Societies
- Medical Colleges
- Pharmaceutical Companies and Industries
- Medical Devices Manufacturing Companies
- Drug Manufacturing Companies and Industries
- Laboratory Technicians and Diagnostic Companies
- Business Entrepreneurs and Industrialists
- Training Institutes
- Microbiologists, Bacteriologists, Virologists
- Parasitologists, Mycologists, Pathologists
- Pharmacists, Epidemiologists, Dermatologists
- Neurologist, Ophthalmologist, Cardiologist
- Health Care Professionals
- Academic Professionals
- Medical & Pharmacy Companies
- GlaxoSmithKline (GSK)
- Gilead Sciences
- Merck & Co.
- Johnson & Johnson
- Eli Lilly
- Astellas Pharma
Related Associations and Societies:
- European Society of Clinical Microbiology and Infectious Diseases
- International Union of Microbiological Societies
- Federation of Infection Societies
- Canadian Society of Microbiologists
- British Infection Association
- Federation of European Microbiological Societies
- Welsh Microbiology Association
- Clinical Virology Network
- American Society for Microbiology
- Society for General Microbiology
- Infectious Diseases Society of America
- International Society for Infectious Diseases
- Clinical Infectious Diseases Society
- National Institute of Allergy and Infectious Disease
- Pediatric Infectious Diseases Society
- Institute for global health and infectious diseases
- International Union Against Tuberculosis and Lung Disease, Paris, France
- Australasian Society for Infectious Diseases
- European Society for Paediatric Infectious Diseases
- Society of Infectious Diseases Pharmacists